JP2005519871A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519871A5
JP2005519871A5 JP2003540308A JP2003540308A JP2005519871A5 JP 2005519871 A5 JP2005519871 A5 JP 2005519871A5 JP 2003540308 A JP2003540308 A JP 2003540308A JP 2003540308 A JP2003540308 A JP 2003540308A JP 2005519871 A5 JP2005519871 A5 JP 2005519871A5
Authority
JP
Japan
Prior art keywords
cells
receptors
antibodies
trail
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003540308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519871A (ja
JP4663232B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/034420 external-priority patent/WO2003038043A2/en
Publication of JP2005519871A publication Critical patent/JP2005519871A/ja
Publication of JP2005519871A5 publication Critical patent/JP2005519871A5/ja
Application granted granted Critical
Publication of JP4663232B2 publication Critical patent/JP4663232B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003540308A 2001-11-01 2002-10-25 腫瘍壊死因子関連アポトーシス誘導リガンドレセプターに対して選択的な抗体と他の治療剤の組み合わせ Expired - Fee Related JP4663232B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34640201P 2001-11-01 2001-11-01
US39147802P 2002-06-24 2002-06-24
PCT/US2002/034420 WO2003038043A2 (en) 2001-11-01 2002-10-25 Combinations of dr5 antibody and other therapeutic agents

Publications (3)

Publication Number Publication Date
JP2005519871A JP2005519871A (ja) 2005-07-07
JP2005519871A5 true JP2005519871A5 (cg-RX-API-DMAC10.html) 2011-01-20
JP4663232B2 JP4663232B2 (ja) 2011-04-06

Family

ID=26994839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003540308A Expired - Fee Related JP4663232B2 (ja) 2001-11-01 2002-10-25 腫瘍壊死因子関連アポトーシス誘導リガンドレセプターに対して選択的な抗体と他の治療剤の組み合わせ

Country Status (20)

Country Link
EP (1) EP1506285B1 (cg-RX-API-DMAC10.html)
JP (1) JP4663232B2 (cg-RX-API-DMAC10.html)
KR (1) KR20040081422A (cg-RX-API-DMAC10.html)
CN (1) CN100506277C (cg-RX-API-DMAC10.html)
AT (1) ATE491019T1 (cg-RX-API-DMAC10.html)
AU (1) AU2002360307B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0213846B8 (cg-RX-API-DMAC10.html)
CA (1) CA2465314C (cg-RX-API-DMAC10.html)
CO (1) CO5650175A2 (cg-RX-API-DMAC10.html)
DE (1) DE60238560D1 (cg-RX-API-DMAC10.html)
HU (1) HU230378B1 (cg-RX-API-DMAC10.html)
IL (2) IL161686A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA04004184A (cg-RX-API-DMAC10.html)
NO (1) NO333828B1 (cg-RX-API-DMAC10.html)
NZ (2) NZ568727A (cg-RX-API-DMAC10.html)
PL (1) PL216750B1 (cg-RX-API-DMAC10.html)
RO (1) RO123525B1 (cg-RX-API-DMAC10.html)
RU (1) RU2313368C2 (cg-RX-API-DMAC10.html)
WO (1) WO2003038043A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200403573B (cg-RX-API-DMAC10.html)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
KR100932577B1 (ko) 2001-05-18 2009-12-17 기린 홀딩스 가부시키가이샤 항 trail-r 항체
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
JP4509570B2 (ja) 2001-07-03 2010-07-21 ジェネンテック, インコーポレイテッド ヒトdr4抗体及びその使用法
EP1436313B1 (en) 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
RU2379056C2 (ru) 2002-11-27 2010-01-20 Айрм Ллс Способы и композиции для индукции апоптоза раковых клеток
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1680138B1 (en) * 2003-10-17 2013-07-17 Novo Nordisk A/S Combination therapy
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Dr5 항체 및 그의 용도
ES2365719T3 (es) 2004-08-06 2011-10-10 Genentech, Inc. Ensayos y procedimientos que utilizan biomarcadores.
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
RU2007112952A (ru) * 2004-09-08 2008-10-20 Дженентек, Инк. (Us) Способы применения лигандов рецепторов смерти и cd20-антител
JP2008513367A (ja) * 2004-09-08 2008-05-01 ジェネンテック・インコーポレーテッド デスレセプターリガンド及びcd20抗体の使用方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2011259844B2 (en) * 2005-02-02 2012-11-01 The Uab Research Foundation Agents and Methods Related to Reducing Resistance to Apoptosis- inducing Death Receptor Agonists
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
BRPI0606791A2 (pt) 2005-02-02 2010-02-09 The Uab Research Foundation métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
JP2006265155A (ja) * 2005-03-23 2006-10-05 Link Genomics Kk 癌の免疫療法
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
BRPI0615997A8 (pt) 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
LT2056675T (lt) 2006-10-12 2019-05-27 Galera Labs, Llc Burnos gleivinės mukozito gydymo būdai
CN101157729B (zh) * 2007-10-23 2011-01-12 南京大学 一种肿瘤坏死因子相关凋亡配体变体及其应用
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
BR112013010574A2 (pt) 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
EP2703486B1 (en) 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
CA3120505C (en) 2011-09-26 2024-11-12 Galera Labs, Llc METHODS OF TREATING DISEASES
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
EP2910573B1 (en) 2012-10-19 2020-02-19 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
CN104383520B (zh) * 2013-08-19 2016-09-07 江苏靶标生物医药研究所有限公司 一种抗肿瘤药物组合物
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
CN107250161A (zh) 2015-01-26 2017-10-13 宏观基因有限公司 包含dr5‑结合结构域的多价分子
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
UA126788C2 (uk) 2015-08-11 2023-02-08 Ґалера Лебз, Елелсі Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність
US20180333491A1 (en) * 2015-08-19 2018-11-22 Sinotau Pharmaceuticals Group Trail receptor-binding agents and uses of same
CN110922481A (zh) 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
MX2018006333A (es) 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
US11007251B2 (en) * 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
MX393974B (es) 2016-05-03 2025-03-24 Galera Labs Llc Terapia de combinacion para tratamiento de cancer.
JP7166634B2 (ja) 2016-09-01 2022-11-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
WO2018138297A1 (en) 2017-01-27 2018-08-02 Kymab Limited Anti-opg antibodies
CN108992671B (zh) * 2017-06-06 2021-02-12 深圳市中科艾深医药有限公司 一种药物组合物及其制备治疗肝损伤的药物中的用途
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
KR101951025B1 (ko) 2017-08-17 2019-02-21 서울대학교산학협력단 세포사멸 수용체 저해제를 유효성분으로 포함하는 cx3cl1 케모카인 과발현으로 인한 질환 예방 또는 치료용 조성물
KR20250004902A (ko) 2017-08-23 2025-01-08 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
CN109810193B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
CN109810194B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
CN118846110A (zh) 2018-09-06 2024-10-29 第一三共株式会社 抗体药物偶联物
BR112021017616A2 (pt) 2019-03-25 2021-11-09 Daiichi Sankyo Co Ltd Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
IL288485B2 (en) 2019-05-29 2026-04-01 Daiichi Sankyo Co Ltd Anti-TROP2 antibody conjugates - a drug for use in cancer treatment
CN114630679A (zh) 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
US12678512B2 (en) 2020-03-06 2026-07-14 Daiichi Sankyo Company, Limited Anti-EGFR antibody-drug conjugate with a cyclic dinucleotide derivative
JPWO2021200131A1 (cg-RX-API-DMAC10.html) 2020-03-30 2021-10-07
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體-免疫賦活化劑共軛物之新穎製造方法
AU2023226367A1 (en) 2022-02-28 2024-10-03 Ube Corporation Antibody-drug conjugate
CN119213128A (zh) 2022-03-09 2024-12-27 株式会社丘阿德 与Eva1蛋白质结合的人源化抗体或其功能性片段、抗体药物缀合物和嵌合抗原受体
CN119997982A (zh) 2022-09-09 2025-05-13 迈里克斯制药有限公司 包含nmt抑制剂的抗体药物偶联物及其用途
GB202403391D0 (en) 2024-03-08 2024-04-24 Myricx Pharma Ltd Novel compounds and their use in therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
TR199902068T2 (xx) * 1997-02-28 1999-12-21 Boehringer Ingelheim Pharmaceuticals, Inc. �ltihap h�crelerinin gen tedavisi ile kendi kendini d�zenleyen apoptozu.
JP2001514888A (ja) * 1997-08-15 2001-09-18 アイドゥン ファーマシューティカルズ, インコーポレイテッド Trailレセプター、これをコードする核酸、およびその使用方法
ATE330972T1 (de) * 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
EP1226161A2 (en) * 1999-09-15 2002-07-31 Genentech, Inc. Apo-2 receptor antibodies
PT2857516T (pt) * 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Similar Documents

Publication Publication Date Title
JP7451627B2 (ja) キメラ受容体及びその使用方法
CN101479296B (zh) Trail受体结合剂和其用途
TWI902626B (zh) 嵌合抗原及t細胞受體以及使用方法
CN113039205B (zh) 靶向cll1的抗体及其应用
RU2623122C2 (ru) Моноклональные антитела и способы их применения
JP2022058876A (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン-4d阻害分子の使用
RU2425841C2 (ru) Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
US7115717B2 (en) Anti-TRAIL-R antibodies
JP2022513434A5 (cg-RX-API-DMAC10.html)
KR101966408B1 (ko) 항체,약학적 조성물 및 이의 용도
IL296874A (en) Antibodies specific for the human poliovirus receptor
JP2002500877A (ja) 細胞死レセプター4(dr4)に対する抗体及びその使用
JP2001502325A (ja) 免疫調整の方法および組成物
CN114057875A (zh) 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途
HUE031037T2 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
BR112013012138B1 (pt) Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
PL211786B1 (pl) Zastosowanie przeciwciała oraz polipeptydu
JP2011116794A (ja) Baffアンタゴニストのための治療養生法
TW200922616A (en) FOXM1 peptide and medicinal agent comprising the same
JP2015529676A (ja) 作用物質および方法
KR102275514B1 (ko) 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
US8440185B2 (en) Compositions and methods for the treatment of immunologic disorders
HK1207870A1 (en) Anti-human sema4a antibodies useful to treat disease
KR102669985B1 (ko) Btla 융합 단백질 작용제 및 이의 용도
JP2021521893A (ja) Tim−3に対する抗体およびその使用